Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TARJW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2024140449A1 ADC18
|
|||||
| Synonyms |
ADC18
Click to Show/Hide
|
|||||
| Organization |
HANGZHOU ADCORIS BIOPHARMA CO., LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
IP140B
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2024140449A1+ADC17+payload
|
Payload Info | ||||
| Linker Name |
WO2024140449A1+ADC17+Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 5 nM | |||
| Method Description |
A Cell line test onNCI-H1975
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 5 nM | |||
| Method Description |
A Cell line test on OE-33
|
||||
| In Vitro Model | Barrett adenocarcinoma, Adenocarcinoma of the esophagus | OE-33 cells | CVCL_0471 | ||